Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer
- 383 Downloads
To evaluate the potential role of dual energy CT (DECT) to visualize antiangiogenic treatment effects in patients with metastatic renal cell cancer (mRCC) while treated with tyrosine-kinase inhibitors (TKI).
26 patients with mRCC underwent baseline and follow-up single-phase abdominal contrast enhanced DECT scans. Scans were performed immediately before and 10 weeks after start of treatment with TKI. Virtual non-enhanced (VNE) and colour coded iodine images were generated. 44 metastases were measured at the two time points. Hounsfield unit (HU) values for VNE and iodine density (ID) as well as iodine content (IC) in mg/ml of tissue were derived. These values were compared to the venous phase DECT density (CTD) of the lesions. Values before and after treatment were compared using a paired Student’s t test.
Between baseline and follow up, mean CTD and DECT-derived ID both showed a significant reduction (p < 0.005). The relative reduction measured in percent was significantly greater for ID than for CTD (49.8 ± 36,3 % vs. 29.5 ± 20.8 %, p < 0.005). IC was also significantly reduced under antiangiogenic treatment (p < 0.0001).
Dual energy CT-based quantification of iodine content of mRCC metastases allows for significantly more sensitive and reproducible detection of antiangiogenic treatment effects.
• A sign of tumour response to antiangiogenic treatment is reduced tumour perfusion.
• DECT allows visualizing iodine uptake, which serves as a marker for vascularization.
• More sensitive detection of antiangiogenic treatment effects in mRCC is possible.
KeywordsMetastatic renal cell carcinoma Therapy monitoring Response evaluation Antiangiogenic treatment Dual energy computed tomography
Abbreviations and acronyms
Dual energy CT density (venous phase)
Dual energy computed tomography
Gastrointestinal stromal tumours
Iodine related attenuation
(metastatic) renal cell cancer
Region of interest
Vascular endothelial growth factor
The scientific guarantor of this publication is Michael Staehler, MD, PhD. The authors of this manuscript declare relationships with the following companies: Bayer, Braco, GSK, Novartis, Pfizer, and Roche. The authors state that this work has not received any funding. No complex statistical methods were necessary for this paper. Institutional Review Board approval was obtained. Written informed consent was obtained from all subjects (patients) in this study. No study subjects or cohorts have been previously reported. Methodology: prospective, case-control study, performed at one institution.
- 9.Graser A, Becker CR, Staehler M (2010) Single-phase dual-energy CT allows for characterization of renal masses as benign or malignant. Investig Radiol 45:399–405Google Scholar
- 17.Atzpodien J, Schmitt E, Gertenbach U et al (2005) Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92:843–846CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Lv P, Liu J, Yan X et al (2016) CT spectral imaging for monitoring the therapeutic efficacy of VEGF receptor kinase inhibitor AG-013736 in rabbit VX2 liver tumours. Eur RadiolGoogle Scholar
- 26.Baxa J, Matouskova T, Krakorova G et al (2015) Dual-phase dual-energy CT in patients treated with erlotinib for advanced non-small cell lung cancer: possible benefits of iodine quantification in response assessment. Eur RadiolGoogle Scholar
- 29.Mileto A, Sofue K, Marin D (2016) Imaging the renal lesion with dual-energy multidetector CT and multi-energy applications in clinical practice: what can it truly do for you? Eur RadiolGoogle Scholar
- 32.Wichmann JL, Hardie AD, Schoepf UJ et al (2016) Single- and dual-energy CT of the abdomen: comparison of radiation dose and image quality of 2nd and 3rd generation dual-source CT. Eur RadiolGoogle Scholar